|  Sign up!  

scientia

Return to Course Listing

 

 

CME: Updates in Migraine Headaches: Best practices and Emerging Therapies in Treatment and Prevention

 


Program Description / Statement of Need:

In this online CME self-learning program:

 

Migraine headache is the leading condition of recurrent cephalalgias of moderate or severe intensity. It is the most common type of headache presented by patients that seek medical treatment, and the World Health Organization (WHO) has ranked migraine in the top fifteen most disabling medical conditions. The condition has been identified as one of the most common neurological disorders, and in the United States, its prevalence in the general population is approximately 12%. In children, the prevalence ranges from 1% to 4% and does not present more commonly in either sex. However, after menarche, its prevalence in females (18%) is approximately three times higher than in males.

 

While the mechanism behind migraine headaches was long thought to be the result of cerebral arterial vasoconstriction and reactive vasodilation, that theory has since been discredited. More recently, research points in the direction of trigeminovascular activation of pain receptors located throughout the central nervous system. Irrespective of cause however, migraine has long been underdiagnosed in the United States in spite the availability of accepted guidelines for diagnostic criteria and effective agents for prophylaxis and treatment.

 

There have been a wide array of advances in the realm of migraine management with respect to pharmacotherapeutic options, including both presently approved as well as more novel, potential ones on the horizon. Helping the clinician discern the role of each of agent – present and future – merits continuing healthcare professional education.

 

Agenda:

 

Introduction, disclosures

Primer and updates on the epidemiology, pathophysiology, clinical presentation, and diagnosis of migraine headaches

  • Statistics, risk factors, social and economic impact
  • Pathophysiology: what is known, what is not
  • Clinical presentation and the barrier of underreporting
  • Clinical practice guideline updates and guidelines’ relative strengths
  • Patient case(s)

Updates in the treatment of patients with migraine headaches

  • Review of present therapies and emerging pharmacotherapy and their respective, anticipated roles
  • Chronic migraine
    • Prophylaxis
      • Calcitonin gene-related peptide ligand and receptor antibodies and antagonists
    • Rescue therapy
      • Novel routes of administration: triptans
      • Novel serotonergic agents
  • A multipronged attack aimed at managing comorbid psychiatric conditions
  • Special considerations for different patient populations
  • Minimizing barriers to care through a more collaborative care, team-based approach between disciplines
  • Best practice: putting it all together
  • Patient case(s)

Summary, conclusions, and best practice recap


 

Target Audience:

Healthcare professionals who are: primary care physicians, neurologists, headache specialists, nurse practitioners, physician assistants, nurses, OB-GYN specialists, pharmacists, and those who otherwise commonly care for or clinically encounter patients who may experience migraine headache.



Program Objectives:

By the end of the session the participant will be able to:

    • Describe the prevalence of migraine symptoms and the impact that these symptoms have on efficacy of anti-migraine therapy and functional status
    • Describe the sometimes variable manifestations (e.g., incidence and clinical presentation) of migraine headaches, depending on age and sex
    • Recall emerging therapies for the treatment and prevention of chronic migraine headache and anticipate their place in therapy
    • Support team-based learning and communication between all clinicians involved with the care of patients suffering with migraines
    • Given a series of patient cases, diagnosis and treat migraine headaches by employing current treatment guidelines, using evidence-based therapy algorithms, and providing individualized approaches to care


    Accreditation:

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

     

    Credit Designation: ScientiaCME designates this educational activity for a maximum of  1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

     

    Pharmacists

     

    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-16-010-H01-P.  ACPE Accreditation effective 7/20/2016, expires 7/20/2018. 

    This is a Knowledge (K)-type activity.



    Release Date: July 20, 2016
    Expiration Date: July 20, 2018

    Faculty: Andrew Charles MD


    Faculty Disclosure and Resolution of COI:

     As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

     

    Faculty Disclosure: Dr. Andrew Charles , MD discloses that he has received financial compensation as consultant or researcher for Takeda, Amgen, Lilly, Trevana, and eNeura


    Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC with no relevent financial disclosures.

     

    Commercial Support Disclosure: This program is supported by an educational grant from AMGEN and Promius.

     

    Viewing Instructions

     

    PC

    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    MAC
    Mac OS 10.2.8
    Safari
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh

     

    *Required to view Printable PDF Version

     

    Privacy Policy

     

    Instructions:


    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.


    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


    Download the Presentation (optional)


     

    View the online program

     

    Perform Post-Test


    Complete the Symposium Evaluation and Request CE Certificate



This program is supported by an educational grant from Amgen and Promius.

 


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.